SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending following an overwhelming shareholder vote to approve the $110 billion merger with Paramount Skydance, marking a major milestone for this media megadeal. While the merger faces continued antitrust scrutiny from regulators and some pushback from Hollywood creators, the market is actively monitoring the deal's path to closing and the implications for industry consolidation.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares recently surged following reports that the streaming company is exploring a potential sale, with major media firms reportedly among the interested parties. Investors are actively debating the likelihood of a buyout, weighing potential premium pricing against Roku's strengthening platform growth and its critical position as a gatekeeper in the connected TV advertising ecosystem.

Anthropic

Anthropic is trending as investors and the community closely track its path toward a highly anticipated IPO, fueled by massive capital raises and intense competition with OpenAI. The discourse is heavily focused on the company's aggressive infrastructure scaling, its strategic partnerships with tech giants, and the ongoing debate regarding the government's role in regulating powerful AI systems.

OpenAI

OpenAI is trending as investors closely track its confidential IPO filing and ongoing discussions regarding a potential U.S. government equity stake, while the community debates the firm's heavy infrastructure spending and long-term valuation prospects compared to rivals like Anthropic. Traders are also actively discussing the company's aggressive acquisition of cloud infrastructure startups and the ripple effects these strategic moves have on the broader AI hardware and software ecosystem.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as investors focus on its integration into the Solana ecosystem and its role as a key decentralized AI infrastructure project. Community sentiment remains highly bullish, with many focusing on its long-term potential as an AI supercomputer while actively debating staking strategies and the importance of subnet developments.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is gaining significant market attention following DOJ clearance of its merger with Warner Bros. Discovery, a move that the community expects will reshape the streaming landscape and create a major competitor to established giants. Despite ongoing scrutiny from state-level antitrust challenges and international regulators, investors remain focused on the potential for massive long-term synergies and the integration of substantial intellectual property assets.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending due to the FDA's full approval of Imdelltra for small-cell lung cancer, which offers a significant survival benefit for patients who have progressed after initial chemotherapy. The community is also closely monitoring the company's cardiometabolic portfolio and ongoing clinical data, while actively debating the potential for M&A activity within the obesity drug space.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to a $180 million public offering following strong Phase 3 results for its CRISPR-based HAE therapy, fueling debates between those highlighting the clinical de-risking and others frustrated by shareholder dilution. Community sentiment is sharply divided, with bulls pointing to the company's long-term commercial potential and institutional accumulation, while bears emphasize the timing of the offering and ongoing volatility in the heavily shorted stock.

TOSHI

TOSHI is trending as the community speculates on potential utility integration with an AI platform, fueling optimism for a supply-crunch rally. Investors are actively debating whether to accumulate during current consolidation phases or rotate into other trending assets while waiting for a definitive breakout.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos is generating significant buzz as investors weigh the potential impact of legislative developments like the Clarity Act against the token's high staking rewards. Community discourse remains divided, with active debates focusing on long-term utility, persistent price stagnation, and the contrast between aggressive staking strategies and bearish sentiment surrounding recent performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients not using insulin.read more...

DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes

DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with...

Here's Why You Should Retain DexCom Stock in Your Portfolio

DXCM banks on CGM market growth, expanding international demand and strong Q1 momentum, though competitive pressures remain a key risk.

DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

Key PointsDexCom is a leading innovator in the continuous glucose monitoring market with a global footprint across 52 countries...

Avanos Medical (AVNS) Up 1.1% Since Last Earnings Report: Can It Continue?

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abbott Addresses a Major Diabetes Care Gap With Tech Innovation

ABT wins the CE Mark for Libre Duo sensors that track glucose and ketones every minute, aiming to spot DKA risks earlier and reduce routine testing.

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American...

The Cooper Companies Gears Up to Post Q2 Earnings: What's in Store?

CooperVision momentum and MyDay/MiSight adoption are likely to fuel COO's Q2, but Japan softness and fertility uncertainty remain key watch points.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

DXCMDexcom Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DXCM News